Tumor MHCII immunity requires in situ antigen presentation by cancer-associated fibroblasts.
D. Kerdidani, E. Aerakis, K.-M. Verrou, P. Stamoulis, K. Goudevenou, A. Prados, C. Tzaferis, I. Vamvakaris, E. Kaniaris, K. Vachlas, E. Sepsas, K. Potaris, A. Koutsopoulos, M. Tsoumakidou
This study shows that cancer-associated fibroblasts present antigens in situ to activate CD4 T cells, enhancing tumor immunity and suggesting new therapeutic strategies.
bioRxiv · Mar 24, 2020Immunology